Human Beta-defensin 1 in Vitiligo

February 5, 2019 updated by: Maha Fathy Elmasry, Cairo University

Estimation of Tissue Level of Human Beta-defensin 1 (HBD-1) in Vitiligo Before and After Narrowband UVB Phototherapy: a Case-control Study

There is a need to know the role of human beta defensin-1 in vitiligo pathogenesis and the probability of finding newer and effective therapy for vitiligo in the future.

Study Overview

Status

Unknown

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Anticipated)

25

Phase

  • Not Applicable

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Patients with non-segmental vitiligo.
  • Both genders.
  • Age more than 18 years old.
  • New cases or cases not receiving any treatment for at least 3 months prior to the study.

Exclusion Criteria:

  • Universal or segmental vitiligo.
  • Any contraindication to phototherapy treatment.
  • History of autoimmune diseases or other systemic diseases.
  • Any other skin disease.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: vitiligo patients
Tissue levels of human beta-defensin 1 in vitiligo patients before and after NB-UVB phototherapy
Other: skin biopsy before and after NB-UVB phototherapy
skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1
Active Comparator: Healthy controls
Tissue levels of human beta-defensin 1 in healthy controls
Other: skin biopsy before and after NB-UVB phototherapy
skin biopsy before and after NB-UVB phototherapy to measure tissue human beta-defensin 1

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Tissue levels of human beta-defensin 1 before and after NB-UVB phototherapy
Time Frame: 6 months to 1 year
6 months to 1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cairo University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

March 1, 2019

Primary Completion (Anticipated)

December 1, 2019

Study Completion (Anticipated)

December 1, 2019

Study Registration Dates

First Submitted

February 5, 2019

First Submitted That Met QC Criteria

February 5, 2019

First Posted (Actual)

February 6, 2019

Study Record Updates

Last Update Posted (Actual)

February 6, 2019

Last Update Submitted That Met QC Criteria

February 5, 2019

Last Verified

February 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Dermatology 12

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe